New soft alkylating agents with enhanced cytotoxicity against cancer cells resistant to chemotherapeutics and hypoxia

Cancer Research

Volumn 67, Issue 5, 2007, Pages 2306-2316

  Patenaude, Alexandre ^a   Deschesnes, Réna G ^a   Rousseau, Jean L C ^a   Petitclerc, Éric ^a   Lacroix, Jacques ^a   Côté, Marie France ^a   C Gaudreault, René ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

( 4 CYCLOHEXYL PHENYL) (4,5 DIHYDRO OXAZOL 2 YL) AMINE; (4 HEPTYL PHENYL) (4,5 DIHYDRO OXAZOL 2 YL) AMINE; ADENINE NUCLEOTIDE TRANSLOCASE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ATRACTYLOSIDE; BETA TUBULIN; BONGKREKIC ACID; CASPASE 8; CASPASE 9; CEU 022; CEU 025; CEU 027; CEU 091; CEU 098; CEU 107; CEU 236; CHLORAMBUCIL; CHLOROETHYLUREA DERIVATIVE; COLCHICINE; CYCLOPHILIN D; CYCLOSPORIN A; N (4 CYCLOHEXYL PHENYL) N' (2 CHLOROETHYL)UREA; N (4 IODO PHENYL) N' (2 CHLORO 1 METHYL ETHYL)UREA; N (4 IODO PHENYL) N' (2 CHLOROETHYL)UREA; N (HEPTYL PHENYL) N' (2 CHLOROETHYL)UREA; N [3 (5 HYDROXY PENTYL) PHENYL] N' (2 CHLOROETHYL)UREA; N [4 (1,1 DIMETHYLETHYL) PHENYL] N' (2 CHLOROETHYL)UREA; N [4 (1,1 DIMETHYLETHYL) PHENYL] N' (ETHYL)UREA; OXA 152; OXA 195; OXAZOLINE DERIVATIVE; PACLITAXEL; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VINBLASTINE; VOLTAGE DEPENDENT ANION CHANNEL 1;

ALKYLATION; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BINDING; DRUG DESIGN; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROSARCOMA; HUMAN; HUMAN CELL; HYPOXIA; MICROTUBULE; MITOCHONDRION SWELLING; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 33947199775     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3824     Document Type: Article

References (50)

1. Béchard P, Lacroix J, Poyet P, C.-Gaudreault R. Synthesis and cytotoxic activity of new alkyl-[3-(chloroethyl)ureido] benzene derivatives. Eur J Med Chem 1994;29:963-6.
2. Lacroix J, Gaudreault RC, Page M, Joly LP. In vitro and in vivo activity of 1-aryl-3-(2-chloroethyl) urea derivatives as new antineoplastic agents. Anticancer Res 1988; 8:595-8.
3. Gaudreault RC, Lacroix J, Page M, Joly LP. 1-Aryl-3-(2-chloroethyl) ureas: synthesis and in vitro assay as potential anticancer agents. J Pharm Sci 1988;77:185-7.
4. Petitclerc E, Deschesnes RG, Cote MF, et al. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Cancer Res 2004;64: 4654-63.
5. Gaudreault RC, Alaui-Jamali MA, Batist G, Bechard P, Lacroix J, Poyet P. Lack of cross-resistance to a new cytotoxic arylchloroethyl urea in various drug-resistant tumor cells. Cancer Chemother Pharmacol 1994;33:489-92.
6. Miot-Noirault E, Legault J, Cachin F, et al. Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma. Invest New Drugs 2004;22: 369-78.
7. Mounetou E, Legault J, Lacroix J, C.-Gaudreault R. Antimitotic antitumor agents: synthesis, structure-activity relationships, and biological characterization of N-aryl-N′-(2-chloroethyl)ureas as new selective alkylating agents. J Med Chem 2001;44:694-702.
8. Legault J, Gaulin JF, Mounetou E, et al. Microtubule disruption induced in vivo by alkylation of β-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating agents. Cancer Res 2000;60:985-92.
9. Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004;23:2861-74.
10. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002; 84:153-66.
11. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341: 233-49.
12. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004;1644:107-13.
13. Tsujimoto Y, Shimizu S. The voltage-dependent anion channel: an essential player in apoptosis. Biochimie 2002;84:187-93.
14. Halestrap AP, Davidson AM. Inhibition of Ca2(+)-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J 1990;268:153-60.
15. Armstrong JS. Mitochondria: a target for cancer therapy. Br J Pharmacol 2006;147:239-48.
16. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002;1555:14-20.
17. Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3β disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 2005;65: 10545-54.
18. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613-21.
19. 13C du terbutylanilino-4 chloroethyluree. J Labelled Comp Radiopharm 1993;XXXIII:1079-82.
20. Patenaude A, Ven Murthy MR, Mirault ME. Mitochondrial thioredoxin system: effects of TrxR2 overexpression on redox balance, cell growth, and apoptosis. J Biol Chem 2004;279:27302-14.
21. Almeida A, Medina JM. A rapid method for the isolation of metabolically active mitochondria from rat neurons and astrocytes in primary culture. Brain Res Brain Res Protoc 1998;2:209-14.
22. de Pinto V, Prezioso G, Palmieri F. A simple and rapid method for the purification of the mitochondrial porin from mammalian tissues. Biochim Biophys Acta 1987; 905:499-502.
23. Kosower EM, Correa W, Kinon BJ, Kosower NS. Glutathione. VII. Differentiation among substrates by the thiol-oxidizing agent, diamide. Biochim Biophys Acta 1972;264:39-44.
24. Mounetou E, Legault J, Lacroix J, C-Gaudreault R. A new generation of N-aryl-N′-(1-alkyl-2-chloroethyl)ureas as microtubule disrupters: synthesis, antiproliferative activity, and β-tubulin alkylation kinetics. J Med Chem 2003;46:5055-63.
25. Moreau E, Fortin S, Desjardins M, Rousseau J, Peticlerc E, C-Gaudreault R. Preparation of a new generation of N-phenyl-N′-(2- chloroethyl)ureas as potential antineoplastic agents: synthesis and cytocidal activity. Bioorg Med Chem 2005;13:6703-12.
26. Cabral F, Sobel ME, Gottesman MM. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin. Cell 1980;20:29-36.
27. Schibler MJ, Barlow SB, Cabral F. Elimination of permeability mutants from selections for drug resistance in mammalian cells. FASEB J 1989;3:163-8.
28. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002;84:131-41.
29. Guidot DM, McCord JM, Wright RM, Repine JE. Absence of electron transport (Rho 0 state) restores growth of a manganese-superoxide dismutase-deficient Saccharomyces cerevisiae in hyperoxia. Evidence for electron transport as a major source of superoxide generation in vivo. J Biol Chem 1993; 268:26699-703.
30. Vieira HL, Haouzi D, El Hamel C, et al. Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ 2000;7:1146-54.
31. Machida K, Hayashi Y, Osada H. A novel adenine nucleotide translocase inhibitor, MT-21, induces cytochrome c release by a mitochondrial permeability transition-independent mechanism. J Biol Chem 2002; 277:31243-8.
32. De Pinto V, al Jamal JA, Benz R, Genchi G, Palmieri F. Characterization of SH groups in porin of bovine heart mitochondria. Porin cysteines are localized in the channel walls. Eur J Biochem 1991;202:903-11.
33. Singh KK, Russell J, Sigala B, Zhang Y, Williams J, Keshav KF. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 1999; 18:6641-6.
34. Lee HC, Yin PH, Lin JC, et al. Mitochondrial Genome Instability And mtDNA depletion in human cancers. Ann N Y Acad Sci 2005;1042:109-22.
35. Costantini P, Belzacq AS, Vieira HL, et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000; 19:307-14.
36. Petrosillo G, Ruggiero FM, Paradies G. Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. FASEB J 2003;17: 2202-8.
37. Morin C, Zini K, Tillement JP. Anoxia-reoxygenation-induced cytochrome c and cardiolipin release from rat brain mitochondria. Biochem Biophys Res Commun 2003;307:477-82.
38. Gicquad C, Auger M, Wong TT, Poyet P. Boudreau N, R CG. Interaction of 4-tert-butyl-[3-(2-chloroethyl) ureido] benzene with phosphatidylcholine bilayers: a differential scanning calorimetry and infrared spectroscopy study. Arch Biochem Biophys 1996;334:193-9.
39. Saint-Laurent A, Boudreau N, Lariviere D, Legault J, Gaudreault RC. Auger M. Membrane interactions of a new class of anticancer agents derived from arylchloroethylurea: a FTIR spectroscopic study. Chem Phys Lipids 2001;111:163-75.
40. Lemasters JJ, Holmuhamedov E. Voltage-dependent anion channel (VDAC) as mitochondrial governator-thinking outside the box. Biochim Biophys Acta 2006; 1762:181-90.
41. Rostovtseva TK, Tan W, Colomhini M. On the role of VDAC in apoptosis: fact and fiction. J Bioenerg Biomembr 2005;37:129-42.
42. Madesh M, Hajnoczky G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol 2001;155:1003-15.
43. Zaid H, Abu-Hamad S, Israelson A, Nathan I, Shoshan-Barmatz V. The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ 2005;12:751-60.
44. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 2004;377:347-55.
45. Gottlob K, Majewski N, Kennedy S, Kandel F, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/ PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001;15:1406-18.
46. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002;277: 7610-8.
47. Majewski N, Nogueira V, Bhaskar P, et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004;16:819-30.
48. Carre M, Andre N, Carles G, et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem 2002;277:33664-9.
49. Sugiyama T, Shimizu S, Matsuoka Y, Yoneda Y, Tsujimoto Y. Activation of mitochondrial voltage-dependent anion channel by a proapoptotic BH3-only protein Bim. Oncogene 2002;21:4944-56.
50. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999;3:287-96.